July 13, 2016
Boosted protease inhibitors, for many years, have been a mainstay for HIV physicians treating people with transmitted drug-resistant strains of HIV. A newer class of drug that also have a high barrier to resistance -- integrase inhibitors -- have also been used in therapy for people with drug-resistant strains of HIV. But do they work as well?
A new study published in JAIDS gives good insight into the question -- and reveals that integrase-containing regimens are as effective as boosted protease inhibitor regimens for people with NNRTI-associated transmitted drug resistance (TDR).
The researchers screened over 3,000 people just starting antiretroviral therapy between 2002 and 2014 and found that about 5% (165 people) had non-nucleoside reverse transcriptase (NNRTI)-associated transmitted drug resistance, with 131 (or 4%) having only NNRTI drug resistance (i.e., no PI- or NRTI-associated mutations). The most common NNRTI mutation ("K103N") was found in 78% of people, followed by a different mutation called Y188L found in 7% of people. Only 2% of people had more than one NNRTI drug-resistant mutation. Since these people were just beginning antiretroviral therapy, i.e., were "ART naive," the mutations were transmitted -- not acquired.
This excerpt was cross-posted with the permission of BETAblog.org. Read the full article.
|Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study|
|Long-Acting Cabotegravir + Rilpivirine for Induction Then Maintenance Therapy|
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.